Umbralisib (TGR-1202) is an investigational drug that is being studied as a treatment for certain types of blood cancers. It is a kinase inhibitor, which means it blocks the activity of certain proteins that are involved in tumor cell growth. It is being studied to see if it can help slow or stop the growth of certain cancers, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and marginal zone lymphoma (MZL).
Umbralisib, sold under the brand name Ukoniq, was an anti-cancer medication for the treatment of two specific types of lymphoma: marginal zone lymphoma (MZL) and follicular lymphoma (FL). It was taken by mouth.
Unfortunately, the FDA withdrew its approval for Ukoniq (umbralisib) in June 2022 due to safety concerns. Updated findings from a clinical trial continued to show a possible increased risk of death in patients receiving Ukoniq.
- Type of drug: Kinase inhibitor
- How it worked: Umbralisib targeted two specific proteins involved in cell growth and survival in cancer cells.
- Side effects: The most common side effects included increased creatinine, diarrhea-colitis, fatigue, nausea, neutropenia, transaminase elevation, musculoskeletal pain, anemia, thrombocytopenia, upper respiratory tract infection, vomiting, abdominal pain, decreased appetite, and rash.